Skip to main content
COVID-19 ResponseInvesting in Potential COVID-19 Treatments

Investing in Potential COVID-19 Treatments

As doctors, public health officials, and other medical experts learn more about COVID-19, Bloomberg Philanthropies is funding two promising studies.

Building on years of deep commitment to Johns Hopkins University and the Bloomberg School of Public Health, Bloomberg Philanthropies committed $3 million to support Bloomberg Distinguished Professor Dr. Arturo Casdevall’s research into the use of plasma from recovered COVID-19 patients.

Taking on the greatest public health challenge of our generation requires urgent and innovative collaboration. As scientists work to develop a vaccine, plasma treatment has the potential to save many lives – including the lives of doctors and healthcare workers on the frontlines of the pandemic.

Mike Bloomberg

Bloomberg Philanthropies is also supporting NYU Langone Health’s research into the connection between COVID-19, autoimmune diseases, and common medications used to treat autoimmune diseases.


What is Convalescent Blood Plasma Therapy?

Top photo: Johns Hopkins University 2020 COVID-19 Research Technologist Kirsten Littlefield conducts research in the lab of Dr. Andy Pekosz at the Bloomberg School of Public Health. Photo credit: Will Kirk/Johns Hopkins University

COVID-19 ResponseInvesting in Potential COVID-19 Treatments